Litzinger D C, Brown J M, Wala I, Kaufman S A, Van G Y, Farrell C L, Collins D
Department of Pharmacology, Amgen, Inc., Thousand Oaks, California 91320, USA.
Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49. doi: 10.1016/0005-2736(95)00268-5.
The present studies describe the biodistribution of cationic liposomes and cationic liposome/oligonucleotide complex following intravenous injection into mice via the tail vein. (111)In-diethylenetriaminepentaacetic acid stearylamide ((111)In-DTPA-SA) was used as a lipid-phase radiolabel. Inclusion of up to 5 mol% DTPA-SA in liposomes composed of 3beta-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC-Chol) and dioleoylphosphatidylethanolamine (DOPE) did not influence liposome formation or size, nor the binding/uptake or fusion of the cationic liposomes with CHO cells in vitro. Moreover, nuclear delivery of oligonucleotide to CHO cells was unaffected by the probe. The biodistribution of liposomes with increasing concentration of DC-Chol (1:4-4:1, DC-Chol/DOPE, mol/mol) at 24 h post-injection revealed no dependence on lipid composition. Uptake was primarily by liver, and accumulation in spleen and skin was also observed. Comparatively little accumulation occurred in lung. Clearance of injected liposomes by liver was very rapid (approximately 84.5% of the injected dose by 7.5 h post-injection). Liposome uptake by liver and spleen were equally efficient in the dose range of 3.33 to 33.33 mg/kg body weight, yet possible saturation of liver uptake at a dose of 66.80 mg/kg may have allowed for increased spleen accumulation. Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic yet transient accumulation of the lipid in lung which gradually redistributed to liver. Similar results were observed when monitoring iodinated oligonucleotide in the complex. Immuno-histochemical studies revealed large aggregates of oligonucleotide within pulmonary capillaries at 15 min post-injection, suggesting the early accumulation in lung was due to embolism. Immuno-histochemical studies further revealed labeled oligonucleotide to be localized primarily to Kupffer cells at 24 h post-injection. Immuno-electron microscopy revealed localization of oligonucleotide primarily to the lumen of pulmonary capillaries at 15 min post-injection. Immuno-electron microscopy revealed localization of oligonucleotide primarily to the lumen of pulmonary capillaries at 15 min post-injection, and to phagocytic vacuoles of Kupffer cells at 24 h post-injection. By these methods, nuclear delivery of oligonucleotide in vivo was not observed. Increasing concentration of mouse serum inhibited cellular binding/uptake of cationic liposomes in vitro, without or with complexed oligonucleotide. We therefore postulate that interaction with plasma components, including opsonin(s), inhibits cellular uptake of the injected liposomes as well as the liposome/oligonucleotide complex, and mediates rapid uptake by Kupffer cells of the liver. These results are relevant to the design of cationic liposomes for efficient delivery of nucleic acid in vivo.
本研究描述了阳离子脂质体和阳离子脂质体/寡核苷酸复合物经尾静脉注射到小鼠体内后的生物分布情况。(111)铟 - 二乙烯三胺五乙酸硬脂酰胺((111)In - DTPA - SA)用作脂质相放射性标记物。在由3β - (N - (N',N' - 二甲基氨基乙烷)氨基甲酰)胆固醇(DC - Chol)和二油酰磷脂酰乙醇胺(DOPE)组成的脂质体中加入高达5摩尔%的DTPA - SA,既不影响脂质体的形成或大小,也不影响阳离子脂质体与CHO细胞在体外的结合/摄取或融合。此外,寡核苷酸向CHO细胞的核内递送不受该探针的影响。注射后24小时,随着DC - Chol浓度增加(1:4 - 4:1,DC - Chol/DOPE,摩尔/摩尔),脂质体的生物分布显示出对脂质组成无依赖性。摄取主要发生在肝脏,同时也观察到在脾脏和皮肤中的积累。在肺中的积累相对较少。肝脏对注射的脂质体的清除非常迅速(注射后7.5小时约为注射剂量的84.5%)。在体重3.33至33.33 mg/kg的剂量范围内,肝脏和脾脏对脂质体的摄取效率相同,但在剂量为66.80 mg/kg时肝脏摄取可能饱和,这可能导致脾脏积累增加。阳离子脂质体与硫代磷酸酯寡核苷酸预孵育会导致脂质在肺中急剧但短暂的积累,随后逐渐重新分布到肝脏。在监测复合物中的碘化寡核苷酸时也观察到了类似结果。免疫组织化学研究显示,注射后15分钟肺毛细血管内有大量寡核苷酸聚集,表明在肺中的早期积累是由于栓塞。免疫组织化学研究进一步显示,注射后24小时标记的寡核苷酸主要定位于枯否细胞。免疫电子显微镜显示,注射后15分钟寡核苷酸主要定位于肺毛细血管腔,注射后24小时定位于枯否细胞的吞噬泡。通过这些方法,未观察到寡核苷酸在体内的核内递送。增加小鼠血清浓度会抑制阳离子脂质体在体外的细胞结合/摄取,无论是否与寡核苷酸复合。因此,我们推测与包括调理素在内的血浆成分的相互作用会抑制注射的脂质体以及脂质体/寡核苷酸复合物的细胞摄取,并介导肝脏枯否细胞的快速摄取。这些结果与用于体内有效递送核酸的阳离子脂质体的设计相关。